CompletedNCT03992781
Depression Symptoms During the First Year of Tofacitinib for Rheumatoid Arthritis
About this title
Read the official source — NCT03992781Observational studyAges 18+Czechia
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Prague and 5 more locationsSee all locations and recruitment
Study information
Study start dateStarted: July 23, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 73
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Locations
- Czechia
- Age range
- Over 18 Years
- Official registry ID
- NCT03992781
- Official title
Show the full official title
NON-INTERVENTIONAL STUDY TO REVIEW THE CHANGES OF DEPRESSION AFTER FIRST-YEAR OF TOFACITINIB TREATMENT IN RHEUMATOID ARTHRITIS (XELJANZ (Registered))
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Prague, Czechia · Brno, Czechia · Břeclav, Czechia
3 more locations
- Ostrava - Trebovice, Czechia
- Velké Bílovice, Czechia
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer.
Who was this study for?
Listed age limits: from 18 years.
